Recombinant Cell Heparin Secretion via Syndecan Domain

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

The production of heparin without using animal-derived tissue is challenging due to contamination risks and the complexity of purifying heparin-like substances that adhere to cell membranes, requiring a more efficient method for industrial production.

Innovation Solution

Introducing a gene encoding the extracellular domain of syndecan into mammalian cells that produce heparin-like substances, allowing for the secretion and collection of these substances from culture supernatants, thereby simplifying the purification process.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If heparin is extracted from animal-derived tissue, then the production source is established, but contamination risks and pathogen propagation occur

Engineering Contradiction:

Improvesafety of heparin productionVSAvoidcontamination with persulfated chondroitin sulphate and pathogen propagation

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The invention extracts and isolates the specific genes responsible for heparin biosynthesis (NDST2, Hs3st1, and SDC) from animal cells and introduces them into mammalian cells. This separates the useful heparin-producing function from the harmful animal-derived contaminants, allowing production of heparin-like substances without using animal tissues.

Inventive Principle:

Principle #2Taking out (Extraction)

Solution Approach 2:

The invention uses mammalian cells as intermediary hosts to produce heparin-like substances. These cells are engineered with specific genes to function as factories for heparin production, mediating between genetic information and the final product while avoiding direct use of animal-derived tissues.

Inventive Principle:

Principle #24Intermediary (Mediator)

2Reliability

If heparin-like substance is produced using mammalian cells, then animal-derived tissue is avoided, but the substance adheres to cell membrane requiring complicated purification

Engineering Contradiction:

Improveavoidance of animal-derived tissueVSAvoidpurification process complexity

Core Design Contradiction:

ReliabilityVSDevice complexity

Solution Approach 1:

The invention extracts only the extracellular domain of syndecan (SDC) and introduces it into mammalian cells. This domain acts as a secretion signal that directs the heparin-like substance to be released into the culture supernatant rather than retained on the cell membrane, simplifying purification by allowing direct collection from the supernatant.

Inventive Principle:

Principle #2Taking out (Extraction)

Solution Approach 2:

Instead of the conventional approach where heparin-like substances are retained on cell membranes and require cell lysis for extraction, the invention inverts the secretion pattern by introducing the SDC extracellular domain, causing the substances to be secreted into the supernatant where they can be easily collected without complicated purification.

Inventive Principle:

Principle #13The other way round (Inversion)

3Ease of manufacture

If chemical or chemoenzymatic synthesis is used, then heparin can be produced, but heterogeneous structural population present in animal-derived heparin cannot be reproduced

Engineering Contradiction:

Improvesynthetic production capabilityVSAvoidstructural heterogeneity of heparin

Core Design Contradiction:

Ease of manufactureVSManufacturing precision

Solution Approach 1:

The invention enables mammalian cells to self-produce heparin-like substances with natural structural heterogeneity by introducing the necessary biosynthetic genes. The cells' own enzymatic systems process the substrates to create the complex, heterogeneous structure characteristic of natural heparin, which cannot be achieved through chemical synthesis alone.

Inventive Principle:

Principle #25Self-service

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

This method enables the efficient production of heparin-like substances in culture supernatants, reducing the need for complicated purification processes and avoiding the use of animal-derived tissues, thus addressing the contamination and production efficiency issues.

Implementation Method 1

introducing a gene encoding the extracellular domain of syndecan into mammalian cells that produce heparin-like substances, allowing for the secretion and collection of these substances from culture supernatants

Methodology Applied

Scientific EffectBiological synthesis and secretion:

Data Source

PatentUS20220380489A1Method for producing heparin-like substance, recombinant cell, and method for producing the same

Publication Date: 2022.12.01 KYUSHU UNIV

AI summary

An object of the present invention is to provide a method for efficiently producing a heparin-like substance without using an animal-derived tissue. The present invention relates to a method for producing a heparin-like substance and the like, the method comprising: (1) preparing a mammalian cell that produces a heparin-like substance, (2) preparing a recombinant cell in which a gene that encodes an extracellular domain of syndecan is introduced into the mammalian cell that produces a heparin-like substance and is prepared in step (1), and (3) culturing the recombinant cell prepared in step (2) in a medium and collecting the heparin-like substance from the resulting culture supernatant.